Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 10/20 | 0.69 |
| ▸ | PRKD2 | Q9BZL6 | 8/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 8/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 8/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 7/20 | 0.69 |
| ▸ | TAOK1 | Q7L7X3 | 7/20 | 0.69 |
| ▸ | MINK1 | Q8N4C8 | 7/20 | 0.69 |
| ▸ | CSNK1G2 | P78368 | 6/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.69 |
| ▸ | GSK3B | P49841 | 6/20 | 0.69 |
| ▸ | CSNK1G3 | Q9Y6M4 | 4/20 | 0.69 |
| ▸ | GSK3A | P49840 | 3/20 | 0.69 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | CLK2 | P49760 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.69 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.69 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523229 | 0.93 | MAPK9 (0.64) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL3525576 | 0.83 | MAPK9 (0.62) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL3523193 | 0.83 | PRKD3 (0.70) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL13342041 | 0.82 | MAPK9 (0.58) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL3529188 | 0.81 | MAPK9 (0.66) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL2745596 | 0.81 | MAPK8 (1.00) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL2745269 | 0.81 | PRKD3 (0.65) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| Hydrochloric Acid SCHEMBL3808465 | 0.81 | MAPK8 (0.98) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL2745996 | 0.81 | MAPK8 (0.70) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 | |
| SCHEMBL5411813 | 0.80 | ALOX5 (0.64) | MAPK9PRKD2MAP4K4CSNK1A1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007028051-A2 | NOVEL IMIDAZO BASED HETEROCYCLES | ABBOTT LABORATORIES (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099925-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K19 | MAPK9 189/4885PRKD2 413/4885MAP4K4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.